DoD Bone Marrow Failure, Investigator-Initiated Research Award
ID: 354817Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Bone Marrow Failure Investigator-Initiated Research Award (IIRA) to support innovative research addressing bone marrow failure (BMF) diseases. This grant aims to fund studies that enhance understanding of BMF conditions, such as aplastic anemia and Fanconi anemia, and to develop effective treatments and cures, with a total funding allocation of $2.44 million for the fiscal year 2024. Eligible applicants include both extramural and intramural organizations, with a requirement for researchers to hold the position of Assistant Professor or higher, and the application process involves a pre-application due by July 17, 2024, followed by a full application due by October 9, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    Files
    Title
    Posted
    The DOD FY24 Bone Marrow Failure Investigator-Initiated Research Award aims to fund innovative research addressing bone marrow failure (BMF) diseases. This federal grant, under the Congressionally Directed Medical Research Programs, has an allocation of $7.5 million for the fiscal year 2024. The funding opportunity seeks applications focusing on understanding the causes and progression of BMF diseases, as well as finding effective treatments and cures. The program prioritizes research on specific BMF conditions, such as aplastic anemia and Fanconi anemia. The application process requires two submissions: a pre-application by July 17, 2024, and a full application by October 9, 2024. There are two funding levels, with limits of $675,000 for early development studies and $850,000 for IND application-enabling efforts. Eligible applicants include both extramural and intramural organizations, with a requirement for researchers to hold the position of Assistant Professor or higher. The document outlines detailed submission guidelines, evaluation criteria, and the need for multidisciplinary collaboration to enhance research impact and translational potential. It stresses rigorous study design while fostering innovative approaches within the scientific community to improve BMF disease outcomes.
    Similar Opportunities
    DoD Bone Marrow Failure, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Bone Marrow Failure Research Program (BMFRP) Investigator-Initiated Research Award, aimed at advancing research on bone marrow failure (BMF) diseases. This grant opportunity includes two funding levels: Funding Level 1 (FL1) focuses on developing mature ideas and translating discoveries into clinical applications, while Funding Level 2 (FL2) supports efforts to facilitate Investigational New Drug (IND) applications for promising therapeutic candidates. With a total estimated funding of $2.44 million available for two awards, the program encourages innovative and collaborative research proposals that address critical questions in BMF disease management. Interested applicants must submit a pre-application by July 17, 2024, with the full application due by October 9, 2024; for assistance, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Multiple Sclerosis, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Multiple Sclerosis Research Program (MSRP) via the Investigator-Initiated Research Award (IIRA). This grant aims to support innovative and high-impact research projects related to Multiple Sclerosis (MS), particularly those that can enhance patient care and quality of life, while excluding clinical trials. The program emphasizes research on central nervous system repair, disease progression correlates, symptom biology, and MS etiology, with a total funding pool of $6 million expected to yield approximately six awards, each up to $1 million over three years. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the Neurofibromatosis Early Investigator Research Award, a federal grant aimed at supporting innovative research in neurofibromatosis (NF). This opportunity is specifically designed for early-stage investigators to develop research projects under the guidance of experienced mentors, focusing on understanding, diagnosing, and treating NF1, NF2, and schwannomatosis disorders. With a total estimated program funding of $640,000 and an expected two awards, each grant will not exceed $200,000 over a performance period of two years. Interested applicants must submit their proposals by October 3, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Investigator-Initiated Research Program
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis Investigator-Initiated Research Program (NFRP) grant to support innovative research projects focused on neurofibromatosis (NF). This program aims to enhance understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis, with a particular emphasis on improving the quality of life for affected individuals, including military personnel and veterans. The total estimated funding for this initiative is $5.36 million, with up to six awards anticipated, and applications must be submitted by October 3, 2024, following a pre-application deadline of September 12, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis New Investigator Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis New Investigator Award to support innovative research in neurofibromatosis (NF). This grant aims to foster the development of early-stage investigators and facilitate the transition of established researchers from other fields into NF research, with a focus on enhancing understanding, diagnosis, and treatment of NF. Eligible applicants include both early-stage and established investigators, and while prior experience in NF research is not required, collaboration with experienced researchers is encouraged. The total estimated funding for this program is $2,880,000, with up to four awards expected, each allowing for direct costs not exceeding $450,000 over a maximum of three years. Interested applicants must submit a pre-application by October 3, 2024, followed by a full application, and can reach the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Reconstructive Transplant Research, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award, aimed at advancing reconstructive transplant research and improving healthcare for military service members and veterans. This grant opportunity seeks proposals that focus on vascularized composite allotransplantation (VCA) and immunotherapy, emphasizing the optimization of immunosuppressive techniques, identification of noninvasive biomarkers for graft rejection monitoring, and development of tissue preservation strategies. With an estimated total program funding of $4 million, individual principal investigator applications can receive up to $1 million, while multiple principal investigator collaborations may secure up to $1.5 million, contingent upon successful peer review. The pre-application deadline is August 7, 2024, and the full application deadline is October 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Early Investigator Research Award (MSRP EIRA) to support innovative research focused on multiple sclerosis (MS) by early-stage investigators. This grant aims to foster the development of postdoctoral researchers with less than four years of experience, encouraging them to collaborate with experienced mentors to address critical needs in MS research, particularly in areas such as CNS repair, disease activity correlates, and MS symptomatology. The total funding available for this program is $1.6 million, with an expected five awards, each providing a maximum budget of $320,000 over two years. Key deadlines include a pre-application due by July 24, 2024, and a full application due by October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Rare Cancers, Idea Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 Rare Cancers Idea Development Award to support innovative research aimed at advancing the understanding and treatment of rare cancers. This grant opportunity encourages proposals that focus on understanding molecular pathways, developing tumor-specific models, or identifying novel therapies, with an emphasis on research that can significantly impact patient outcomes. The total funding available for this program is approximately $17.5 million, with individual awards capped at $350,000 over a three-year period, and applications are due in two stages: a pre-application by June 17, 2024, and a full application by September 23, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    CDMRP Neurofibromatosis Exploration-Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis Exploration-Hypothesis Development Award, aimed at funding innovative research related to neurofibromatosis (NF). This grant supports the exploration of high-risk, high-gain concepts to enhance understanding and treatment of NF1, NF2, and schwannomatosis, with an estimated total program funding of $1.12 million and the expectation to fund approximately seven projects. The application process is two-tiered, requiring pre-applications by September 12, 2024, and full applications by October 3, 2024, with a focus on innovation, research feasibility, and impact on NF research and patient care. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Peer Reviewed Cancer, Impact Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Peer Reviewed Cancer Impact Award, aimed at funding high-impact cancer research that benefits Service Members, Veterans, and their families. This grant opportunity seeks to support mature research projects that address critical cancer issues, with a focus on translational or clinical research that demonstrates the potential for significant near-term impact on patient outcomes. With an estimated total program funding of $16 million and the expectation of awarding approximately 10 grants, applicants must submit a pre-application by June 21, 2024, followed by a full application due by September 26, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.